Active Surveillance for Throat Cancer

This trial explores whether some throat cancer patients can safely skip radiation after surgery. It targets those with HPV-related oropharyngeal cancer who show no signs of the virus in their blood post-surgery. The researchers aim to monitor these patients closely using Active Surveillance With ctHPVDNA (NavDx®) to detect any recurrence early, avoiding the side effects of radiation. Patients with HPV-related throat cancer who have undergone surgery might be suitable candidates, particularly if they are not currently smoking. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of participants.

The trial does not specify if you need to stop taking your current medications, but it does exclude those currently taking Disease Modifying Rheumatoid Drugs (DMRDs) or immunosuppressive medication. It's best to discuss your specific medications with the trial team.

Studies have shown that ctHPVDNA testing, used to monitor HPV-related throat cancer, can detect cancer recurrence earlier than traditional methods. This early detection plays a crucial role in effective disease management. Research indicates that patients generally find this method easy to handle, as it relies on blood tests instead of treatments that often cause side effects.

Researchers are excited about using ctHPVDNA for active surveillance in throat cancer because it offers a cutting-edge way to monitor patients after surgery without the need for immediate radiation therapy. Unlike traditional methods that often involve radiation as a precautionary measure, this approach uses a blood test to detect circulating tumor DNA, allowing for a more personalized and less invasive monitoring process. This means fewer side effects and a focus on treating only those who show signs of recurrence, potentially improving quality of life while maintaining effective cancer control.

Research has shown that using ctHPVDNA (a type of DNA found in the blood related to HPV) to monitor patients with HPV-related throat cancer holds promise. In one study, 94.5% of patients with a positive ctHPVDNA test experienced cancer recurrence, while those with negative tests rarely did. Another study found that all patients with no detectable ctHPVDNA after surgery remained cancer-free. In this trial, participants will undergo active surveillance with ctHPVDNA testing after surgery. This testing can help identify early signs of cancer returning, allowing for prompt treatment. Overall, using ctHPVDNA in regular check-ups could improve outcomes by detecting recurrences early.¹³⁶⁷⁸